Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib drug-drug interaction pharmacokinetic study in RET-altered advanced solid tumors
2025-523158-15-00Phase 4Authorised
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pralsetinib in Nonhematologic neoplasms, sponsored by Rigel Pharmaceuticals, Inc. Primary endpoints: AUC0-inf of probe substrates and relevant metabolites, AUClast of probe substrates and relevant metabolites and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
pralsetinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-523158-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523158-15-00.